| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $9.8M | +3.3% |
| SG&A Expense | $6.3M | +34.8% |
| Operating Income | -$16.1M | -10.6% |
| Net Income | -$19.4M | +14.2% |
| EPS (Basic) | $31.22 | -54.4% |
| EPS (Diluted) | $31.22 | -54.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $7.4M | +31.4% |
| Current Assets | $7.7M | +32.9% |
| Total Assets | $7.8M | +32.1% |
| Current Liabilities | $4.8M | +274.4% |
| Total Liabilities | $5.0M | -73.5% |
| Stockholders' Equity | $2.8M | +121.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$15.2M | -22.0% |
| Capital Expenditures | $96K | -7.7% |
| Investing Cash Flow | -$96K | +7.7% |
| Financing Cash Flow | $17.0M | +24.0% |
| Free Cash Flow | -$15.3M | -21.8% |